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ABSTRACT

The synthesis of 2,4-disubstituted pyrimidine derivatives is described. The synthetic route
involved the addition reaction of lithiated intermediates, mostly heterocycles, to position 4 of 2chloropyrimidine to give a dihydropyrimidine intermediate which was oxidized back to a
pyrimidine. This was followed by nucleophilic aromatic substitution with various amines of the
chlorine in the position 2. A number of compounds were prepared which showed binding
towards various serotonin receptors in preliminary biological evaluation.
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Introduction

The 5-hydroxytryptamine (5-HT) is an important neural transmitter which signals a
variety of biological and neurological functions. Recent discoveries and advances in the study of
the 5-HT receptor family have opened the area to much further work and review.

NH2
HO
N
H

Figure 1. 5-Hydroxytryptamine (serotonin).

The 5-HT7 receptors are a large family of receptors, ranging from 5-HT1 to 5-HT7, named
so in order of discovery. The newest member of the 5-HT family, 5-HT7, was discovered about
10 years ago.
The 5-HT7 receptor is a G-protein coupled receptor consisting of 2 cystine cross-links
and seven transmembrane domains [1]. As with all 5-HT receptors, 5-HT7 has a high affinity for
serotonin, as well as a number of structurally similar compounds, leading to the difficulty of
selective 5-HT receptor study.
Four basic types of 5-HT7 receptors have been identified in rat and human physiology:
5-HT7a, 5-HT7b, 5-HT7c, and 5-HT7d. The difference between these isoforms is the amino acid
chain length. In the cases of 5-HT7a and 5-HT7b, the isoforms appear to be legitimately different
receptors, though physiological distribution appears fairly uniform. 5-HT7c, found only in rats,
1

and 5-HT7d, found exclusively in humans, appear to be the result of transcription errors; with
both receptors including species-specific exons during transcription. The 5-HT7c and 5-HT7d
receptors do not appear to possess any special biological roles [2]. Furthermore, the 5-HT7a and
5-HT7b receptors appear to possess similar binding properties, and differ primarily in their
location in the body.

Table 1. The numbers of amino acids in the rat and human 5-HT7 receptors [2].

Human
Rat

5-HT7a
445
448

5-HT7b
432
435

5-HT7c
470

5-HT7d
479
-

The receptor 5-HT7 is distributed throughout several areas of the body. This receptor is
found primarily in the brain, and to a lesser extent in parts of the digestive tract. Messenger RNA
analysis has indicated the greatest presence in the hippocampus, thalamus, and the
suprachiasmatic nucleus of the hypothalamus [3]. Lower levels have been found in the ileum,
coronary artery, stomach, and colon [2].
A variety of functions have been attributed to the 5-HT7 receptor. The majority of these
biological roles are neurological or regulatory in function and include the learning, sleep cycle
interference, thermal regulation, and mood altering effects.
5-HT7 receptor synthesis has been inhibited in rats using antisense RNA fragments, with
the goal of studying receptor effect. The observed result was a decrease in the rat’s contextual
fear conditioning. This conditioning, resulting from hippocampus activity, allows the rat to
interpret environmental factors resulting in a fear response. An end result of the study was to
show that 5-HT7 receptors are produced and utilized during times of acute stress [3].
Numerous antidepressants have been demonstrated to exhibit some effect on the 5-HT7
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receptor. This link between 5-HT7 and depression is further exhibited by the apparent moodinfluencing effects and effects on the sleep rhythm. In fact, 5-HT7 antagonists have been
demonstrated to alter rapid eye movement (REM) sleep, resulting in a longer time to achieve
REM sleep and a shorter duration of REM sleep [3].
Some other activities of the 5-HT7 receptor include the 8-hydroxy-2-(di-n-propylamino)tertraline (8-OH-DPAT) induced hypothermia in guinea pigs and the smooth muscle control. The
latter phenomenon creates the potential of 5-HT7 acting drugs to function as anti-migraine
medication [3].
A key difficulty in the study of 5-HT7 receptors is its strong structural similarity to
several of the receptor families, including 5-HT1 and 5-HT2a. Upon discovery of the 5-HT7
receptor a review of previously used 5-HT ligands revealed that many of the ligands previously
deemed selective in fact exhibited a high affinity for the 5-HT7 family in addition to the targeted
5-HT receptor. These include the agents methiothepin, 5-carboxamidotryptamine, 8-OH DPAT,
and mesulergine [2]. The majority of the 5-HT7 ligands showed the greatest affinity for the 5HT2a receptor, followed by several other receptors [1].

Receptor

+

Inhibitor

Ki

Receptor-Inhibitor

[R][I]
Ki =

[RI]
pKi = -log(Ki)

Figure 2. A simplified equation for receptor-inhibitor binding and Ki calculation using molar concentrations of the
receptor and inhibitor.

As with all inhibitors, the inhibitor affinity for the 5-HT7 receptor is quantified by study
of the equilibrium between the inhibitor-receptor complex and free receptor. The value generally
3

reported, Ki, is an equilibrium constant (inhibition constant) indicating the ratio of receptorinhibitor complex against the free receptor.
Inhibitor efficacy is generally regarded to increase as the Ki value grows smaller; as a
lower concentration of inhibitor would be required to occupy the same number of receptors.

Reported 5-HT7 Receptor Ligands

H 2N
O

OH
N
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N
H

8-OH-DPAT 5- HT 7 pKi = 6. 3
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N
N
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O
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Figure 3. Structures of several 5-HT ligands. These compounds were previously believed to be selective against
various other 5-HT receptors, but have since been shown to possess significant 5-HT7 affinity.

Following the initial discovery of the 5-HT7 receptor, numerous pharmaceutical
companies rushed into screening studies in an effort to identify selective 5-HT7 ligands. One of
the first successes was reported by SmithKline Beecham; they found several active antagonists
with a moderate affinity for the 5-HT7 receptor; [2].

4

Figure 4. The lead SmithKline Beecham compound for the SB series of 5-HT7 ligands.

A study of the chiral isomers of the compound give in Figure 4 found that the binding
affinity was highest for the RR isomer (pKi = 6.9). The piperidine chiral center was eliminated
via placing the methyl group in position 4, and a variety of aromatic rings were used in place of
the initial naphthalene system. Several of these derivatives showed increased activity towards 5HT7 receptors. The most selective was, SB-258719, (Figure 5) [2].

Figure 5. The SmithKline Beecham 5-HT7 ligand SB-258719 and derivatives.

The next study undertaken was to lock the interconnecting alkyl chain into a heterocyclic
5

ring. Pyrrolidine derivatives proved more active than the piperidine analogs, and further
derivatives of the aromatic substituent yielded several active and selective compounds, including
SB-258741 (pKi = 8.5) and SB-269970 (pKi = 8.9) [2].

Figure 6. SB-269970, a promising 5-HT7 ligand, and several similar SmithKline Beecham compounds. This series
features a shorter, locked alkyl chain, which improved affinity for the 5-HT7 receptor.

While SB-269970 exhibited exceptional selectivity and inhibition, the compound was a
poor drug candidate, due to its short lifespan in vivo, which in turn was attributed to the presence
of the phenol group. A large variety of SB-269970 derivatives were tested, largely consisting of
modified heterocycles, but results were not encouraging.
A subsequent series of compounds involved replacement the phenol ring of SB-269970
with less polar arenes and the substitution of the position 4 methyl group with a variety of
aromatic systems (Figure 7). This series included compound SB-656104, which had a pKi of
8.70, and bioavailability of 16%; allowing for further study of these compounds as drug
candidates.

6

Figure 7. SmithKline Beecham 5-HT7 ligands from the SB series, including SB-656104, which feature aromatic
substitutients on the piperidine ring.

Figure 8. Two lead compounds and derivatives from the 5-HT7 receptor ligands developed by Kilkuchi et al [4].

Another group of compounds, developed by Kikuchi et al. [4] that have demonstrated
7

both affinity and selectivity toward the 5-HT7 receptor are tetrahydropyridoindoles (Figure 8).
Most of this family of compounds exhibited higher 5-HT7 receptor binding affinities (in
the low nanomolar range), but showed little selectivity against other 5-HT receptors. The key
factors determined by Kikuchi et al. were the interconnecting alkyl chain length, the nitrogenattached heterocyclic substituent attached to the chain, and the group attached to the
secondary/tertiary nitrogen in the main ring.
Studies showed that compounds with a four carbon chain were most selective for 5-HT7
in the presence of 5–HT2. Second, the main ring system nitrogen could either remain secondary
or the inclusion of an alkyl chain could produce a tertiary system. Brief efforts were made using
both methyl and ethyl chains, which yielded a slight decrease in selectivity of the methyl
derivative and a significant drop in both affinity and selectivity for the ethyl derivative. These
results were attributed to the increased size of the nitrogen-bound group blocking receptor
binding.
Lastly, the nitrogen-attached heterocycle was modified. Several bicyclic systems were
used, including tetrahydroisoquinoline, imidazopyridine, pyrazolopyridine, thienopyridine, and
furopyridine. Of the five bicyclic systems used the isoquinoline compound exhibited the best
binding affinity for 5-HT7, while thienopyridine produced the most selective compound with
only a slightly reduced 5-HT7 affinity.

8

Figure 9. Several of the more active 5-HT7 receptor ligands developed by Raubo et al. [5].

Raubo et al. have pursued a class of compounds (Figure 9) that are structurally similar to
the SmithKline Beecham series of sulfones [5]. This new series uses a sulfone group between a
phenyl ring and a cyclobutane attached to a short alkyl chain with a nitrogen heterocycle on the
opposing end, as exemplified by Raubo A. While these compounds exhibited high 5-HT7
affinity, considerable progress towards selectivity was achieved when the cyclobutane ring was
removed from the molecule, leading to a structure considerably closer to the SmithKline
Beecham class of ligands.
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Figure 10. 5-HT7 receptor ligands developed by Warner-Lambert [2].

Warner-Lambert Company has developed several classes of 5-HT7 ligands [2]. One
group, based on the lead compound (Warner-Lambert A, Figure 10) has shown some promise as
a 5-HT7 ligand. Several derivatives of Warner-Lambert A were studied. The efforts were made
to replace the amide group with some other carbonyl. However, these efforts were uniformly
unsuccessful, as each derivative possessed lower 5-HT7 affinity than the initial amide.
Next was a brief effort to alter the substituent on the imine group. However, this too lead
to a considerable decrease in 5-HT7 affinity and was not further pursued. Instead, a new group of
derivatives were created by replacing the naphthalene system with a variety of other aromatic
systems (Figure 11). Several of these showed improvement in affinity, though selectivity against
5-HT2A was poor.

10

Figure 11. Derivatives of the Warner-Lambert class of compounds with modifications to the amide group.

Returning to the initial naphthalene compound (Warner-Lambert A), a new group of
derivatives were prepared by replacement of the amide bound methyl group. Most of the active
derivatives contained six-membered rings and were substituted with proton accepting groups. It
was speculated that the binding pocket has some space which can readily incorporate large
groups as well as form hydrogen bonds [2].

Figure 12. Warner-Lambert compounds modified with piperidine groups.

The next step was the placement of a substituted piperidine ring (attached at position 4)
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to the amide group (Figure 12). Various aryl groups were attached to the piperidine nitrogen,
though the resulting compounds possessed a greater affinity for the 5-HT2A receptor than for the
5-HT7.

Figure 13. Warner-Lambert compounds which exhibited favorable 5-HT7 affinity, but also possessed 5-HT1A
affinity.

Combination of these factors produced a ligand with considerable 5-HT7 affinity, but
drastically higher 5-HT1A affinity. Efforts were made to change the piperidine to a piperazine,
but a significantly larger 5-HT1A affinity remained.

Figure 14. The lead DuPont 5-HT7 ligand and methoxy derivatives.
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A class of tetrahydroquinolines were developed by the DuPont Pharmaceutical Company
[2] which showed affinity for the 5-HT7 receptor, though selectivity was marginal. The initial
compounds were synthesized with a variety of aromatic substituents connected to the
tetrahydroquinoline via an ethyl chain. It was determined that the inclusion of methoxy groups
improved affinity (Figure 14).

Figure 15. 5-HT7 ligands developed by DuPont with tetrahydroquinoline substituents.

Using a phenyl ring as the aromatic substituent, a several groups were placed along the
tetrahydroquinoline in an effort to further increase 5-HT7 affinity as show in Figure 15. The more
active compound a methoxy group at position 8.
The final compound (Figure 16) was had a decent affinity for the 5-HT7 receptor, but
exhibited poor selectivity against 5-HT1D, 5-HT2C, and 5-HT6.
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Figure 16. The end DuPont 5-HT7 ligand.

Figure 17. 5-HT7 ligands developed by Shionogi and Company.

A large class of 5-HT7 ligands have been developed by the Shionogi and Company [2].
This class consists of a series of 2,4,6 trisubstituted pyridines. The general structure (Figure 17)
contains substituted aryl rings at positions 2 and 4 of the pyridine, and a methylene group
forming a link between the pyridine and piperazine nitrogens. Further aromatic substitution has
been placed on the 4 position of piperazine.

14

Figure 18. Shionogi and Company 5-HT7 ligands with position 2 aryl derivatives.

While limited data was provided by Shionogi and Company, a variety of substituted
pyridine compounds were reported (Figures 17 & 18). The active compounds contained a
pyridine moiety substituted at position 2 with a methoxy or hydroxy group. Little selectivity was
observed between ortho and meta substitution, but a notable drop in affinity was seen for para
substitution.

Figure 19. Pyrimidine based 5-HT7 receptor ligands developed by Bristol-Myers Squibb, possessing an IC50 below
50nM.

Bristol-Myers Squibb and Company have reported the development of pyrimidine and
triazine based compounds possessing 5-HT7 receptor activity. While selectivity data was not
included, and limited binding data is available; it is known that numerous compounds were
developed with an IC50 value of under 50nM.
15

Figure 20. Triazine ring based 5-HT7 ligands with an IC50 below 50nM.

The compounds consisted of 2-4 disubstituted pyrimidines (Figure 19) or 2,4,6trisubstituted triazines (Figure 20). All the reported substituents were secondary amino groups
with short alkyl chains attached to substituted aromatic rings.

Past Pyrimidine Research

The synthesis of the target pyrimidine compounds was accomplished following a
procedure first developed at Georgia State University in 1988, and expanded upon in 1990 [6,7].
Early work began with the addition of lithiated intermediates to the pyrimidine ring, with
the 1,6-dihydropyrimidine intermediate oxidized back to the pyrimidine (Scheme 1). This
allowed for additional lithium addition/substitution reactions (Equation 1) to obtain 4,6disubstituted 2-chloropyrimidines.
16

Scheme 1

Further study along this line lead to the development of a series of 2,4-disubstiuted and
2,4,6-trisubstituted pyrimidines [9]. Along with the previously established lithium
addition/substitution reaction, these compounds were prepared using amines to displace
chlorines at positions 2 and 6 (Equation 2). Further study of these compounds indicated
favorable pKi against the serotonin receptor 5-HT2A.
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Discussion

The chemistry described above has been used to synthesize the pyrimidine derivatives in
this work. The following text describes chemistry conducted as part of this thesis.
The first step of ligand synthesis was the preparation of the desired organolithium
reagent. This was accomplished by either lithium bromine exchange (Equation 3) or lithiation
(Equation 4).

Lithium-bromine exchange was conducted in anhydrous THF under dry nitrogen at low
temperature. An excess of the bromine reagent was used to ensure the complete reaction of nbutyllithium and prevent the formation of an undesired butylpyrimidine side product.
Lithiation of 17 (Equation 4) was accomplished under mild conditions.

18

Scheme 2

After the intermediates, 15, 16, 18, had been generated, the mixtures were cooled to
-78 ˚C and a solution of 2-chloropyrimidine (1) in anhydrous THF was introduced dropwise over
a period of several minutes. Upon addition, 15, 16, & 18 were allowed to react with 1 for 30 min
at -78 ˚C, then the temperature was raised to -30 ˚C over 1 h. Any remaining lithium compounds
were quenched with water and the mixture was treated with the oxidative reagent DDQ (2,3dicyano-4,5-dichlorobenzoquinone). Following this procedure, the product 20-22 was extracted
with dichloromethane.
Purification of 20-22 was accomplished using silica gel chromatography, eluting with a
mixture of hexanes and dichloromethane.

19

Figure 21. Compounds 23-25 prepared as described in literature [7, 10, 11].

Three additional compounds 23-25 (Figure 21) were obtained following previously
established protocol [7, 10, 11].

Scheme 3

Displacement of the chlorine atom at position 2 of compounds 20-25 was accomplished
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by treatment with various piperazines (Schemes 3 and 4). Products 29-33, 37, & 38 were
obtained.
Upon completion of the reaction, the crude product was purified on a chromatotron using
silica gel and eluting with a mixture of dichloromethane and methanol

Scheme 4

Structures of the synthesized compounds were verified 1H-NMR spectroscopy and
elemental analysis of the hydrobromide or hydrochloride salt. For example, an AB system was
observed in the 1H-NMR system for the H5-H6 moiety of the pyrimidine in all compounds. The
chemical shifts, approximately 8 ppm for H6 and 6.0-7.5 ppm for H5, are consisted with the
literature values. The methylpiperazine moiety was also easily identified by the singlet-triplettriplet pattern occurring at roughly 2.3 ppm, 2.5 ppm, and 3.9 ppm respectively.
Scheme 5
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One compound of special interest is compound 21, which was observed to undergo two
independent reactions upon treatment with N-methylpiperazine. One reaction is the displacement
of the chlorine atom at position 2 of the pyrimidine. The second reaction appears to be a variant
of Michael addition, with the involvement of the vinyl substituent at the pyrimidine. The
mechanism is suggested in Scheme 5. It should be noted that the alternative reactivity may
involve the 1,4-addition first, as shown.
The structural studies on the resulting product 41 involved 1H-NMR spectroscopy and
mass spectrometry. The finial structural determination was performed using elemental analysis.
During efforts to record a 13C spectrum of the HBr salt of 41 in DMSO at 70 ˚C the
compound underwent elimination of N-methylpiperazine, resulting in the complete conversion to
the initially expected mono-piperazine product, compound 42 (Equation 5).

22

This compound was subsequently studied by 1H-NMR spectroscopy, which confirmed
both the loss of N-methyl piperazine and the presence of two new vinylic protons. Mass
spectrum confirmed the expected molecular weight of 280 g/mol, and the elemental analysis of
the carefully prepared hydrochloride salt supported the proposed structure.

Biological Activity

Figure 22. Serotonin and the general structure of the active pyrimidine compounds.

The 5-HT7 active pyrimidines have exhibited a series of general characteristics.
Compounds developed by past researchers have proven most active with basic or proton
accepting groups in position 4, specifically the 3-furyl group. Along similar lines, piperazine or
4-substituted piperazine has proven virtually essential for a high 5-HT7 affinity. Non-polar
groups, specifically short aliphatic chains, have been shown to boost 5-HT7 affinity as well.
The biological activity of the synthesized compounds 29-33, 37, 38, 40, & 41 are
23

reported in Table 2 as -log Ki or –log Ks (pKi and pKs, respectively). Ki is the inhibitive constant
and Ks is the estimated inhibitive constant.
The values of pKi and pKs both report receptor inhibition, and vary on method and
accuracy. Both values were calculated based on the displacement of a radioactive label via the
examined receptor; pKs values consisted of a simpler preliminary test and, as such, are less
accurate. The reported pKi values were determined much more thoroughly, and as such have a
greater degree of accuracy.

Table 2. The biological activity of the synthesized ligands 29-37 against the 5-HT2A and 5-HT7 receptor.

Compound

pKi 5-HT2A

pKs 5-HT2A

pKi 5-HT7

pKs 5-HT7

-

6

-

-

5.67

-

-

4

-

7

6.12

-

29, C18H18N4O • 1.5 HBr

30, C14H20N4O • HBr • 1.5 H2O

31, C14H17N5 • 2 HBr • 1.5 H2O

24

-

4

5.71

-

5.39

-

-

6

5.82

-

-

5

5.57

-

-

5.89

-

-

-

-

32, C17H18N4S2 • 1.5 HBr • 2 H2O

33, C23H22N4 • 1.5 HBr • 2 H2O

37, C14H18N4O2 • 2 HBr • 0.5 H2O

38, C14H15N5O • 2 HBr • 0.5 H2O

41, C22H32N6 • 4 HCl • 1 H2O

25

-

-

-

-

42, C17H20N4 • 3.5 HBr • 2 H2O

Experimental

General

All glassware was dried at 80 °C and cooled under nitrogen. All organolithium reactions
were preformed in anhydrous tetrahydrafuran, distilled immediately before usage with
benzophenone and sodium. All compounds were transferred using syringes, and all moisture
sensitive reactions were preformed under dry nitrogen. All biological activity testing was
conducted at the Institute of Pharmacology, the Polish Academy of Sciences.

Generation of Lithium Reagents

Phenanthren-9-yllithium (15) and 1-(phenylvinyl)-lithium (16) were generated by the
bromine-lithium exchange of 9-bromophenanthrene (13) and α-bromostyrene (14) with nbutyllithium (2.5M, 2 mmol) at -78 °C in THF for 30-90 s. (3,4-Dihydro-2H-pyran-6-yl)lithium
(18) was prepared by treatment of 3,4-dihydro-2H-pyran (17) and t-butyllithium at -78 °C; the
mixture was allowed to reach 0 °C over 50 min.

26

Synthesis of 4-Substituted 2-Chloropyrimidines

A solution of 2-chloropyrimidine (2.0 mmol, 229 mg) in THF was added dropwise to
solutions of 15, 16, & 18 over a period of 5 min. The solutions were allowed to react for 30 min
at -78 °C, then the temperature was raised to -20 °C over a period of 1 h. Then the mixtures were
quenched with water (1 ml) and treated with a solution of DDQ (2.0 mmol, 454 mg) in THF (1
ml). After 15 min, the mixtures were treated with a solution of aqueous NaOH (3M, 18 ml, 6.0
mmol) and products 4-(3,4-dihydro-2H-pyran-6-yl)pyrimidine (20), 2-chloro-4-(phenanthren-9yl)pyrimidine (21), and 2-chloro- 2-chloro-4-(1-phenylvinyl)pyrimidine (22) were extracted with
dichloromethane.
Additional compounds 2-chloro-4-(furan-3-yl)pyrimidine (23), 2-chloro-4-(pyridin-3yl)pyrimidine (24), and 4-(2,2'-bithiophen-5-yl)-2-chloropyrimidine (25) were prepared from 3bromofuran, 3-bromopyridine, and 2,2'-biothiphene using the previously published literature [7,
10, 11]
All products were purified using a chromatotron with normal phase EMD 60PF254 silica
gel. The products were eluted using a combination of hexanes/dichloromethane.

Amination

Piperazine derivatives 4-(3-furyl)-2-(4-phenylpiperazino)pyrimidine (29), 4-(3,4-dihydro2H-pyran-6-yl)-2-(4-methylpiperazino)pyrimidine (30), 2-(4-methylpiperazino)-4-pyridin-3ylpyrimidine (31), 4-(2,2'-bithiophen-5-yl)-2-(4-methylpiperazino)pyrimidine (32), 2-(4methylpiperazino)-4-(9-phenylanthryl)pyrimidine (33), 2-(4-methylpiperazinol)-4-(2-(4-
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methylpiperazino)-1-phenylethyl)pyrimidine (41) were prepared from 20-25 (0.6 mmol) and
phenylpiperazine or methylpiperazine (3 equivalents, 6 equivalents for 41) in toluene (3 ml)
under reflux for 3 h.
Secondary amine compounds 4-(furan-3-yl)-N-(2-morpholinoethyl)pyrimidin-2-amine
(37) and N-(3-(1H-imidazol-2-yl)propyl)-4-(furan-3-yl)pyrimidin-2-amine (38) were prepared
from 23: 37 (0.60 mmol of 23 with 1.94 mmol of 2-morpholinoethanamine, 16 h, 100 °C) 38
(0.70 mmol of 23 with 2.15 mmol of 3-(1H-imidazol-2-yl)propan-1-amine, 16 h, 100 °C).
All products were purified using a chromatotron with normal phase EMD 60PF254 silica
gel. The products were eluted using a combination of dichloromethane/methanol.

Salt Formation

All salts were formed from products 29-33, 37, 38, and 41 by preparing a solution of the
individual product in a minimum amount of methanol (0.5-1 ml) and adding a slight excess of
hydrobromic acid (48%, 0.30 ml, 1.9 mmol) or hydrochloric acid (12.4M, 0.15 ml, 1.9 mmol).
Hydrobromide/hydrochloride salt crystals were formed by precipitation upon addition of Et2O
(5 ml). The resulting salts were dried under vacuum at 80 °C for several hours. The salt of
product 42 was produced using a dilute solution HBr (2.1M, 1.5 ml, 0.7 mmol) to avoid
disruption of the vinyl group. The salts of 41 and 42 proved too hydroscopic to collect via
filtration, and were instead collected by removal of the solvent under vacuum.

2-Chloro-4-(3-furyl)pyrimidine (23) This compound was obtained following the previously
described procedure [7].
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1

H NMR (CDCl3, 400 MHz) δ 6.90 (d, J = 1.6 Hz, 1H) δ 7.31 (d, J = 5.0 Hz, 1H) δ 7.54 (d, J =

1.6 Hz, 1H) δ 8.22 (s, 1H) δ 8.57 (d, J = 5.0 Hz, 1H); literature 1H NMR (CDCl3, 400 MHz) δ
6.90 (d, J = 1.6 Hz), δ 7.30 (d, J = 5.2 Hz), δ 7.53 (d, J = 1.6 Hz) δ 8.21 (s) δ 8.54 (d, J = 5.2
Hz).

4-(3-Furyl)-2-(4-phenylpiperazino)pyrimidine hydrobromide (29 • 1.5 HBr) A solution of 2chloro-4-(3-furyl)pyrimidine (87 mg, 0.48 mmol) was allowed to react under reflux in toluene
(1ml) with 1-phenylpiperazine (233 mg, 1.44 mmol) for 3 h at 100 °C. Purification and salt
formation were accomplished as described above.
This compound had a mp of 223-225 °C; yield 62%; 1H NMR (DMSO-d6, 400 MHz) δ 3.33 (s,
4H), δ 4.00 (s, 4H) δ 6.93 (m, 1H) δ 7.05 (dd, J = 1.6, 5.2 Hz, 1H) δ 7.17 (m, 3H) δ 7.29 (t, J =
7.2 Hz, 2H) δ 7.84 (d, J = 1.6 Hz, 1H) δ 8.41 (d, J = 5.6 Hz, 1H) δ 8.56 (s, 1H).
Anal. Calcd. for C18H18N4O • 1.5 HBr: C, 50.54; H 4.50; N 13.10. Found: C, 50.16; H, 4.30; N,
12.75.

4-(3-Furyl)-N-(2-morpholin-4-ylethyl)pyrimidin-2-amine hydrobromide (37 • 2 HBr • 0.5
H2O) A solution of 2-chloro-4-(3-furyl)pyrimidine (108 mg, 0.60 mmol) was reacted under
reflux in toluene (2 ml) with 4-(2-aminoethyl)morpholine for 16 h. Purification and conversion
to a hydrobromide salt were accomplished as described in the general procedure.
This compound had a mp of 143-146 °C; yield 69%; 1H NMR (free base, CDCl3, 400 MHz) δ
2.49 (t, J = 4.4 Hz, 5H) δ 2.59 (t, J = 6 Hz, 2H) δ 3.55 (q, J = 6 Hz, 2H) δ 3.71 (t, J = 4.4 Hz, 5H)
δ 5.78 (s, 1H) δ 6.66 (d, J = 5.2 Hz, 1H) δ 6.85 (m, J = 1.8 Hz, 1H) δ 7.48 (d, J = 1.8 Hz, 1H) δ
8.07 (s, 1H) δ 8.25 (d, J = 5.2, 1H).
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Anal. Calcd for C14H18N4O2 • 2 HBr • 0.5 H2O: C, 37.77; H, 4.75; N 12.59. Found: C, 37.78; H,
4.76; N, 12.20.

4-(3-Furyl)-N-(1H-imidazol-2-yl)propyl)pyrimidin-2-amine hydrobromide (38 • HBr • 0.5
H2O) 2-Chloro-4-(3-furyl)pyrimidine (130 mg, 0.7 mmol) was reacted under reflux in toluene
(2 ml) with 3-(1H-imidazol-2-yl)propan-1-amine (270 mg, 2.15 mmol) at 100 °C for 17 h.
Purification and salt formation were accomplished as described above.
This compound had an mp of 234-236 °C; yield 62%; 1H NMR (free base, CDCl3, D2O, 400
MHz) δ 2.09 (m, J = 6.8 Hz, 2H) δ 3.46 (t, J = 6.8 Hz, 2H) δ 4.04 (t, J = 6.8 Hz, 2H) δ 6.70 (d, J
= 5.2 Hz, 1H) δ 6.84 (m, J = 2.2 Hz, 1H) δ 6.94 (s, 1H) δ 7.06 (s, 1H) δ 7.49 (m, 2H) δ 8.06 (m,
J = 2.2 Hz, 1H) δ 8.24 (d, J = 5.2 Hz, 1H).
Anal. Calcd. for C14H15N5O • 2 HBr • 0.5 H2O: C, 38.30; H 4.12; N, 15.91. Found: C, 38.23; H,
3.93; N, 15.78.

2-Chloro-4-(3,4-dihydro-2H-pyran-6-yl)pyrimidine (22)
A solution of 3,4-dihydro-2H-pyran (223 mg, 2.65 mmol) in dry THF (1 ml) was cooled to
-70 °C under nitrogen and treated dropwise with a solution of t-butyllithium (1.6M, 4.62 ml, 2.89
mmol). The temperature of the mixture was raised to 0 °C over 50 min, lowered to -65 °C. A
mixture of 2-chloropyrimidine (303 mg, 2.64 mmol) in THF (1 ml) was added dropwise. The
temperature was raised to -10 °C over 80 min, and the mixture was worked up and purified
according to the general procedure.
This compound was obtained in 17% yield, brown oil; 1H NMR (CDCl3, 400 MHz) δ 1.95 (m,
2H) δ 2.30 (d, J = 4.4 Hz, 2H) δ 4.18 (t, J = 5.2 Hz, 2H) δ 6.41 (s, 1H) δ 7.14 (d, J = 5.2 Hz, 1H)
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δ 8.57 (d, J = 5.2 Hz, 1H).

4-(3,4-Dihydro-2H-pyran-6-yl)-2-(4-methylpiperazino)pyrimidine hydrobromide (30 • 1.25
HBr • 0.5 H2O)
2-Chloro-4-(3,4-dihydro-2H-pyran-6-yl)pyrimidine (92 mg, 0.47 mmol) was allowed to react
under reflux with 1-methylpiperazine (139 mg, 1.39 mmol) in toluene (1 ml) at 100 °C for 3h.
The resulting solution was purified according to the above procedure.
This compound had a mp of 192-194 °C; yield 80%; 1H NMR (free base, CDCl3, 400 MHz)
δ 1.91 (m, 2H) δ 2.25 (d, 4.4 Hz, 2H) δ 2.33 (s, 3H) δ 2.47 (t, J = 4.8 Hz, 4H) δ 3.86 (t, J = 4.8
Hz, 4H) δ 4.15 (t, J = 4.8 Hz, 2H) δ 6.21 (m, 1H) δ 6.74 (d, J = 5.2 Hz, 1H) δ 8.32 (d, J = 5.2 Hz,
1H).
Anal. Calcd. for C14H20N4O • 1.25 HBr • 0.5 H2O: C, 45.39; H, 6.05; N 15.12. Found: C, 45.71;
H 6.08; N, 15.27.

2-Chloro-4-(pyridin-3-yl)pyrimidine (24)
This compound was obtained using the previously published procedure [11].
1

H NMR (CDCl3, 400 MHz) δ 7.49 (dd, J = 4.8, 7.6, 1H) δ 7.72 (t, J = 4.8, 10 Hz 1H) δ 8.46 (m,

1H) δ 8.73 (d, J = 5.2 Hz, 1H) δ 8.79 (s, 1H) δ 9.27 (s, 1H); literature 1H NMR (CDCl3) δ 7.40
(ddd, J = 8.1, 4.8, 0.9 Hz, 1H) δ 7.71 (ddd, J = 8.4, 0.9 Hz, 1H) δ 7.78 (dd, J = 8.4, 2.4 Hz, 1H) δ
8.30 (ddd, J = 8.1, 2.1, 2.0 Hz, 1H), δ 8.66-8.68 (m, J = 4.8, 2.4, 1.8, 0.9 Hz, 2H) δ 9.18 (dd, J =
2.1, 0.9 Hz, 1H).
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2-(4-Methylpiperazino)-4-(pyridin-3-yl)pyrimidine hydrobromide (31 • 2 HBr • 1.5 H2O)
A solution of 2-chloro-4-(pyridin-3-yl)pyrimidine (80 mg, 0.42 mmol) was treated with 1methylpiperazine (125 mg, 1.25 mmol) in toluene (1 ml) under reflux for 3 h. The reaction was
purified as described in the general procedure.
This compound had a mp of 163-165 °C; yield 84%; 1H NMR (DMSO-d6, 400 MHz,) δ 2.87 (d,
J = 3.6 Hz, 3H) δ 3.13 MHz (m, 2H) δ 3.37 (m, 2H) δ 3.55 (m, 2H), δ 4.91 (m) δ 7.55 (d, J = 5.2
Hz, 1H) δ 7.91 (m, J = 5.2 Hz, 1H) δ 8.66 (d, J = 5.2 Hz, 1H) δ 8.92 (m, J = 5.2 Hz, 2H) δ 9.53
(s, 1H), δ 9.93 (s, 1H).
Anal. Calcd. for C14H17N5 • 1.5 H2O • 2 HBr: C, 37.86; H 4.99; N, 15.77. Found: C, 38.02; H,
4.46; N, 15.58.

2-Chloro-4(2,2'-bithiophen-5-yl)pyrimidine (25) This compound was obtained following the
procedure reported without characterization in published literature [12].
1

H NMR (CDCl3, 400 MHz) δ 7.07 (m, 1H) δ 7.22 (d, J = 4 Hz, 1H) δ 7.32 (t, J = 1.2, 4.4 Hz,

2H) δ 7.43 (d, J = 5.4 Hz, 1H) δ 7.71 (d, J = 4 Hz, 1H) δ 8.52 (d, J = 5.4, 1H).

4-(2,2'-Bithiophen-5-yl)-2-(4-methylpiperazino)pyrimidine hydrobromide (32 • 1.5 HBr • 2
H2O)
2-Chloro-4(2,2'-bithiophen-5-yl)-pyrimidine (103 mg, 0.37 mmol) was allowed to react with 1methylpiperazine (111 mg, 0.0011 mmol) in toluene (1 ml) for 3 h under reflux. The resulting
compound was isolated and converted to a salt using the purification procedure described above.
This compound had a melting point of 187-190 °C; yield 76%; 1H NMR (free base, CDCl3, 400
MHz) δ 2.36 (s, 3H) δ 2.51 (t, J = 5.0 Hz, 4H) δ 3.92 (t, J = 5.0 Hz, 4H) δ 6.79 (d, J = 5.2 Hz,
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1H) δ 7.05 (m, J = 4.0 Hz, 1H) δ 7.18 (d, J = 4 Hz, 1H) δ 7.27 (m, 2H) δ 7.55 (d, J = 4 Hz, 1H) δ
8.29 (d, J = 5.2 Hz, 1H).
Anal. Calcd. for C17H18N4S2 • 1.5 HBr • 2 H2O: C, 40.85; H 4.74; N, 11.21. Found: C, 40.54; H,
4.41; N, 11.04.

2-Chloro-4-(9-phenylanthryl)pyrimidine (20)
A solution of 9-bromoanthracene (400 mg, 1.56 mmol) in THF (2 ml) was treated with
butyllithium (2.5 M, 0.6 ml, 1.5 mmol) at -78 °C under dry nitrogen for 30 seconds. A solution
of 2-Chloropyrimidine (178 mg, 1.55 mmol) in THF (1 ml) was added dropwise. The reaction
was allowed to proceed for 40 minutes, until the temperature reached -30 °C. The work up and
purification were preformed as described in the general procedure.
This compound was obtained at a yield 44%; oil; 1H NMR (CDCl3, 400 MHz) δ 7.59 (m, J = 4.8
Hz, 2H) δ 7.66 (m, 2H) δ 7.88 (m, 2H) δ 8.09 (d, J = 8 Hz, 1H) δ 8.66 (m, 2H) δ 8.71 (d, J = 8
Hz, 1H).

2-(4-Methylpiperazino)-4-(9-phenylanthryl)pyrimidine hydrobromide (33 • 1.5 HBr • 2
H2O)
2-Chloro-4-(9-phenylanthryl)pyrimidine (200 mg, 0.69 mmol) was allowed to react with 1methylpiperazine (207 mg, 2.07 mmol) in toluene (1 ml) under reflux at 100 °C for 3 h. This
compound was purified and the salt was formed as described above.
This compound had a mp of 195-198 °C; yield 78%; 1H NMR (free base, CDCl3, 400 MHz) δ
2.32 (s, 3H) δ 2.48 (t, J = 10 Hz, 4H) δ 3.95 (t, J = 10 Hz, 4H) δ 6.81 (d, J = 5.2 Hz, 1H) δ 7.58
(m, 2H) δ 7.65 (m, 2H) δ 7.89 (m, 2H) δ 8.28 (d, J = 8.4 Hz, 1H) δ 8.44 (t, J = 5.2 Hz, 1H) δ
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8.71 (m, J = 8.0, 8.4 Hz, 2H).
Anal. Calcd. for C23H22N4 • 1.5 HBr • 2 H2O: C, 53.97; H 5.42; N, 10.95. Found: C, 54.35; H,
5.04; N, 10.96.

2-Chloro-4-(1-phenylvinyl)pyrimidine (21)
A solution of α-bromostyrene (416 mg, 2.27 mmol) in THF (5 ml) was cooled to -78 °C under
dry nitrogen and n-butyllithium (2.5 M, 0.9 ml, 2.25 mmol) was added dropwise over 1min. 2Chloropyrimidine (227 mg, 2.4 mmol) in THF (1 ml) was introduced drop wise. The solution
was allowed to react for 25 min at -78 ˚C, the raised to -40 °C over 40 min. The resulting
solution was subject to work-up and purification as described in the general procedure.
This compound was obtained at a yield of 38%; brown oil; 1H NMR (CDCl3, 400 MHz) δ 5.75
(d, J = 1.2 Hz, 1H) δ 6.45 (d, J = 1.2 Hz, 1H) δ 7.09 (d, J = 5.2 Hz, 1H) δ 7.30 (m, 2H) δ 7.38
(m, 3H) δ 8.51 (d, J = 5.2 Hz, 1H).

2-(4-Methylpiperazino)-4-(2-(4-methylpiperazino)-1-phenylethyl)pyrimidine hydrochloride
(41 • 4 HCl • 1 H2O)
2-Chloro-4-(1-phenylvinyl)pyrimidine (143 mg, 0.66 mmol) was dissolved in toluene (1 ml) and
treated with 1-methylpiperazine (198 mg, 1.98 mmol) for 3 h at 100 °C. The purification and salt
formation occurred as described above.
This compound was obtained at a 34% yield; as a thick brown oil; 1H NMR (free base, CDCl3,
400 MHz) δ 2.33 (m, 6H) δ 2.34 (m, 7H) δ 2.50 (m, 9H) δ 2.88 (dd, J = 6.0, 6.8 Hz, 1H) δ 3.38
(dd, J = 4.8, 8.0 Hz, 1H) δ 3.87 (t, J = 5.2 Hz, 4H) δ 4.06 (m, 1H) δ 6.37 (d, J = 5.2 Hz, 1H) δ
7.21 (m, 1H) δ 7.27 (m, 2H) δ 7.34 (m, 2H) δ 8.32 (d, J = 5.2 Hz, 2H).
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Anal. Calcd. for C22H32N6 • 4 HCl • 1 H2O: C, 48.54; H 7.04; N, 15.44. Found: C, 48.16; H,
7.21; N, 15.17.

2-(4-Methylpiperazino)-4-(1-phenylvinyl)pyrimidine hydrobromide (42 • 3.5 HBr • 2 H2O)
A sample of 2-(4-Methylpiperazino)-4-(2-(4-methylpiperazino)-1-phenylethyl)pyrimidine
hydrobromide was dissolved in DMSO and heated to 70 °C for 40 min. The mixture was cooled
to 25 °C and treated with excess sodium carbonate, and the pure product was collected by
extraction with dichloromethane.
This compound was a hydroscopic brown oil; yield 99%; 1H NMR (free base, CDCl3, 400 MHz)
δ 2.34 (s, 3H) δ 2.46 (m, J = 3.0 Hz, 4H) δ 3.90 (m, J = 3.0 Hz, 4H) δ 6.70 (m, 1H) δ 7.50 (m,
2H) δ 7.60 (m, 1H) δ 8.08 (m, 2H) δ 8.53 (m, 1H).
Anal. Calcd. for C17H20N4 • 3.5 HBr • 2 H2O: C, 34.05; H 4.62; N, 9.34. Found: C, 34.30; H,
4.73; N, 8.92.
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